Applied Molecular Evolution Company Description
Natural selection doesn't happen fast enough for Applied Molecular Evolution (AME). The biotech firm uses its AMEsystem technology to improve genes and proteins for medical uses. Employing what AME calls directed evolution, the company adjusts a protein's amino acids one at a time until the protein acquires the desired therapeutic characteristics. AME's biopharmaceuticals have increased the potency of MedImmune's anti-tumor drug Vitaxin (which AME helped developed). The company is a subsidiary of Eli Lilly
View the Comprehensive Company Description for Applied Molecular Evolution
The Company Description provides a historical perspective of Applied Molecular Evolution's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Applied Molecular Evolution's evolution in the marketplace.
